---
category: news
title: "Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration"
excerpt: "Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company, announced today that a successful preclinical study has shown its drug candidate LP-184 is able to inhibit tumor growth and improve survival in animal models of glioblastoma (GBM)."
publishedDateTime: 2021-08-19T07:50:00Z
originalUrl: "https://www.morningstar.com/news/pr-newswire/20210819da80715/lantern-pharma-announces-positive-preclinical-data-in-glioblastoma-gbm-with-drug-candidate-lp-184-and-expands-gbm-research-collaboration"
webUrl: "https://www.morningstar.com/news/pr-newswire/20210819da80715/lantern-pharma-announces-positive-preclinical-data-in-glioblastoma-gbm-with-drug-candidate-lp-184-and-expands-gbm-research-collaboration"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Morningstar, Inc.
  domain: morningstar.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://mma.prnewswire.com/media/1216507/Lantern_Pharma_Logo.jpg"
    width: 400
    height: 296
    isCached: true

secured: "pI1c6lrCJLBzQ6fl8HzaHp66oMO7Ww16Yu+ikqp+UmreNw9HsC4thruBuP+2aMMrs8NyA/055KqZtjlfoeHGopPZRpQqziGP37gZiz/0BtEkQCqBHOW1BhE58+sZlempO/EAGUxo0dTJBOoYr78xWfwCHfJYRZ5V90zbWL1ygnWBBRNQuUPaUqFX3+d+08qTRvXNpK7gh4myXInduNhQjgzzoxSKe2//g28EufdEjXqK9rEd7+mOIlsAHxWnMYwC5Px9+cVqWiWLLIyiGRuKFsc67pvRb8DtvFJg5xaKg4AZNAgm8DGJJa9aNsMhmk6VYZuhxDeDA29XdIrkShHq1zDiVcWaPJYKJgH09IzWO6A=;BTO97tVyvMHZ+Qig9aJUSg=="
---

